HealthLinx shares spike on ovarian cancer test data

Shares of Australia's HealthLinx shot up after the biotech announced that its diagnostic test for ovarian cancer outperformed the diagnostic tool now in use. Investigators said that OvPlex significantly reduced the number of diagnostic errors made in analyzing blood samples. Most women aren't diagnosed with ovarian cancer until the disease has progressed to a late stage, severely reducing their odds of surviving the disease for more than a few years. Story

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.